Innovent registers Phase 1 trial of IBI3046 in Chinese patients with overweight or obesity
A new Phase 1 study of Innovent's IBI3046 is recruiting participants in China, testing the drug alone and combined with mazdutide.
This week's update covers a single newly registered trial for Innovent Biologics.
- IBI3046, an injectable drug being tested for overweight or obesity, has entered a Phase 1 trial sponsored by Innovent Biologics (Suzhou) Co. Ltd. that is recruiting as of its September 9, 2026 posting date. The study is a randomized, double blind, placebo controlled Phase I study evaluating safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of IBI3046 in Chinese participants with overweight or obesity, comprising four phases: single ascending dose (SAD), multiple ascending dose (MAD), IBI3046 administration after mazdutide discontinuation, and IBI3046 in combination with mazdutide.1 The trial plans to enroll 128 participants (estimated)1 and lists a start date of 2026-09-23 (actual)1 with estimated primary completion on 2028-07-16 (estimated)1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.